Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant lipiodolized intra-arterial chemotherapy versus GEMOX versus surveillance after curative treatment of hepatocellular carcinoma on cirrhosis
2006-005456-32Phase 3Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2007
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, oxaliplatin, cisplatin and ethiodized oil in hepatocellular carcinoma (HCC) and Cirrhosis (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Recurrence-free survival. Started Feb 2007; status: terminated.
02
Drugs
gemcitabineoxaliplatincisplatinethiodized oil
03
Conditions
hepatocellular carcinoma (HCC)Cirrhosis
Beyond the preview
Go deeper on 2006-005456-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005456-32.